IP Library Granted Patent US 10,849,525
Granted Patent B2
US 10,849,525 · App. 15/576,676 · Granted Dec 1, 2020

Monitoring brain neural activity

Inventors: John Louis Parker (Artarmon, AU); Gerrit Eduard Gmel (Artarmon, AU)
Assignee: Saluda Medical Pty Ltd
A61B5/0484A61B5/048A61B5/4064A61B5/4082A61B5/4836A61B5/6868A61B5/7275A61N1/0529A61N1/0534A61N1/36135G16H40/63G16H50/20A61B5/4848
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,849,525
App. No.
15/576,676
Granted
Dec 1, 2020
Kind
B2
Abstract

Monitoring brain neural activity comprises repeatedly applying electrical stimuli to evoke neural responses in the brain. Neural responses evoked by the stimuli are recorded. The recorded neural responses are assessed for changed characteristics over time, to monitor a time-varying effect on the recorded neural responses of local field potentials arising from a source other than the electrical stimuli.

Claims (28)

1. A method of monitoring brain neural activity, the method comprising:

repeatedly applying electrical stimuli to evoke evoked compound action potentials in a brain;

recording evoked compound action potentials evoked by the stimuli,

assessing the recorded evoked compound action potentials for changed characteristics over time, to monitor a time-varying effect of local field potentials on the evoked compound action potentials, the local field potentials arising from a source other than the electrical stimuli.

2. The method of claim 1 , wherein assessing the recorded evoked compound action potentials comprises assessing the amplitude of the recorded evoked compound action potentials.

3. The method of claim 1 wherein assessing the recorded evoked compound action potentials comprises assessing spectral content of the recorded evoked compound action potentials.

4. The method of claim 3 , further comprising assessing amplitude variations arising in a range of 0.6 to 3 Hz so as to assess a heartbeat.

5. The method of claim 3 , further comprising assessing amplitude variations arising in a beta-band oscillation range of 7-35 Hz.

6. The method of claim 1 wherein the time-varying effect is compared to healthy ranges and/or monitored for changes over time in order to diagnose a disease state.

7. The method of claim 1 wherein the to time-varying effect is compared to healthy ranges and/or monitored for changes over time in order to determine a therapeutic effect of a therapy.

8. The method of claim 1 , further comprising indicating a therapeutic response, based on the time-varying effect.

9. A brain neurostimulator device comprising:

at least one stimulus electrode configured to be positioned in a brain and to deliver electrical stimuli to the brain;

at least one sense electrode configured to be positioned in the brain and to sense evoked compound action potentials evoked by the stimuli;

a pulse generator configured to apply electrical stimuli from the at least one stimulus electrode to the brain;

measurement circuitry configured to record brain evoked compound action potentials sensed by the at least one sense electrode in response to the electrical stimuli; and

a processor for assessing the recorded evoked compound action potentials for changed characteristics over time, to monitor a time-varying effect of local field potentials on the evoked compound action potentials, the local field potentials arising from a source other than the electrical stimuli.

10. A computer program product comprising computer program code means for monitoring brain neural activity, the computer program code means configured to:

repeatedly apply electrical stimuli to evoke evoked compound action potentials in the brain;

record evoked compound action potentials evoked by the stimuli; and

assess the recorded evoked compound action potentials for changed characteristics over time, to monitor a time-varying effect of local field potentials on the evoked compound action potentials, the of local field potentials arising from a source other than the electrical stimuli.

11. The brain neurostimulator device of claim 9 , wherein the processor is further configured to assess the recorded evoked compound action potentials by assessing the amplitude of the recorded evoked compound action potentials.

12. The brain neurostimulator device of claim 9 wherein the processor is further configured to assess the recorded evoked compound action potentials by assessing spectral content of the recorded evoked compound action potentials.

13. The brain neurostimulator device of claim 12 wherein the processor is further configured to assess amplitude variations arising in a range of 0.6 to 3 Hz so as to assess a heartbeat.

14. The brain neurostimulator device of claim 12 , wherein the processor is further configured to assess amplitude variations arising in a beta-band oscillation range of 7-35 Hz.

15. The brain neurostimulator device of claim 9 wherein the processor is further configured to compare the time-varying effect to healthy ranges, and/or monitor the time-varying effect for changes over time, in order to diagnose a disease state.

16. The brain neurostimulator device of claim 9 wherein the processor is further configured to compare the time-varying effect to healthy ranges, and/or monitor the time-varying effect for changes over time, in order to determine a therapeutic effect of a therapy.

17. The brain neurostimulator device of claim 9 wherein the processor is further configured to indicate a therapeutic response, based on the time-varying effect.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2020
From: SALUDA MEDICAL PTY LTD
To: CLOSED LOOP MEDICAL PTY LTD
Reel/Frame 054354/0677 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2017
From: PARKER, JOHN LOUIS; GMEL, GERRIT EDUARD
To: SALUDA MEDICAL PTY LTD
Reel/Frame 044202/0784 →
Priority Claims (1)
AU 2015902022 · May 31, 2015 · national
Continuity (1)
Related Publication 20180132747A1 · May 17, 2018
Cited By (6)
US 12,285,263 US 12,329,527 US 12,369,826 US 12,376,780 US 12,667,306 US 12,702,836